anemia in pregnancy 2029 Size, Share & Forecast Analysis 2025–2033

anemia in pregnancy 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

anemia in pregnancy 2029 Market Size | CAGR 7.3 Forecast 2033

anemia in pregnancy 2029 Size, Share & Forecast Analysis 2025–2033

anemia in pregnancy 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

anemia in pregnancy 2029 Market Overview

Anemia in pregnancy refers to a condition where a pregnant woman's hemoglobin level falls below the normal threshold, compromising maternal health and fetal development. The anemia in pregnancy 2029 market size is a critical barometer for healthcare investment, reflecting the demand for iron supplements, intravenous (IV) iron therapies, and nutritional fortification solutions. According to market intelligence (Grand View Research, 2024), the global market was valued at approximately USD 2.3 billion in 2025 and is projected to reach USD 3.4 billion by 2029, delivering a CAGR of about 9% during the 2026‑2029 forecast period. This growth outlook is driven by rising prevalence of maternal anemia, expanding public‑health initiatives, and heightened awareness of prenatal nutrition across emerging economies.

Loading chart…

Key forces shaping the industry include: (1) Regulatory momentum—governments in Asia‑Pacific and Africa are tightening anemia screening and supplement mandates; (2) Technological advances—next‑generation IV iron formulations with improved safety profiles are gaining market share; and (3) Supply‑chain resilience—local manufacturing of fortified foods reduces reliance on imports. The largest region by revenue remains Asia‑Pacific, driven by high birth rates and extensive public‑health programs, while Sub‑Saharan Africa emerges as the fastest‑growing region, propelled by international donor funding and rising awareness of maternal nutrition. These dynamics collectively underpin a robust market forecast and signal sustained industry expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.14 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK plc; Merck & Co., Inc.; Pfizer Inc.; Bayer AG; Sanofi; AbbVie Inc.; AstraZeneca PLC; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S; Johnson & Johnson
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Expanding prenatal screening programs in emerging economies, driven by government maternal health initiatives, are boosting demand for iron‑supplement therapies, propelling the anemia in pregnancy 2029 market size upward.

Rising prevalence of iron‑deficiency anemia linked to dietary transitions and higher maternal age, combined with reimbursement reforms that favor oral and IV iron formulations, underpins a robust growth forecast through 2029.

Restraints2 items

Stringent regulatory pathways for novel IV iron complexes, especially in the EU and US, extend time‑to‑market and increase development costs, tempering the anemia in pregnancy 2029 market expansion.

Persistent price sensitivity among public health systems, compounded by generic competition for oral ferrous salts, compresses margins and limits adoption of premium products.

Opportunities2 items

Integration of point‑of‑care hemoglobin analyzers with digital health platforms enables real‑time anemia detection, opening a high‑value channel for personalized supplement regimens and expanding the market’s addressable base.

Emerging biosimilar pipelines for IV iron (e.g., ferric carboxymaltose) offer cost‑effective alternatives, allowing manufacturers to capture market share in cost‑constrained regions while supporting the overall growth forecast.

Challenges2 items

Supply chain vulnerabilities for key raw materials such as ferrous sulfate, exacerbated by geopolitical trade disruptions, threaten consistent product availability and could destabilize the anemia in pregnancy 2029 market size projections.

Variability in clinical practice guidelines across regions leads to fragmented prescribing patterns, complicating market penetration strategies for multinational firms.

Market Segmentation

Loading chart…

Oral iron therapy remains the largest application segment in the anemia in pregnancy 2029 market, accounting for roughly 45% of total revenue. This segment includes ferrous sulfate, gluconate, and fumarate formulations administered as tablets or syrups. Its dominance is driven by low unit cost, extensive distribution networks, and established clinical guidelines that prioritize oral iron as first‑line treatment for iron‑deficiency anemia during gestation. The segment’s contribution is amplified by high prevalence of mild to moderate anemia in low‑ and middle‑income regions, where oral regimens are preferred due to limited access to infusion facilities. Market growth is further supported by ongoing product innovations such as sustained‑release and gastro‑protective formulations, which improve compliance and reduce gastrointestinal side effects. Consequently, oral iron therapy underpins the overall market size, serving as the baseline from which ancillary therapies and diagnostic services expand.

Intravenous iron therapy represents the second‑largest application, contributing approximately 30% of the 2029 market valuation. This segment encompasses ferric carboxymaltose, iron sucrose, and ferumoxytol administered in clinical or hospital settings. Demand is propelled by the need for rapid hemoglobin correction in cases of severe anemia, intolerance to oral iron, or when adherence is compromised. The segment’s growth trajectory is reinforced by expanding obstetric care facilities in emerging economies and by reimbursement policies that increasingly recognize IV iron as cost‑effective for preventing transfusion‑related complications. Technological advancements, such as lower‑dose infusion protocols and safety‑enhanced formulations, further broaden its applicability. As a high‑margin, resource‑intensive segment, intravenous iron therapy adds significant value to the overall market, complementing oral products and shaping service‑based revenue streams.

Vitamin supplementation—primarily folic acid and vitamin B12—accounts for about 15% of the anemia in pregnancy 2029 market. This application segment targets micronutrient deficiencies that coexist with iron‑deficiency anemia, especially in populations with limited dietary diversity. Clinical practice guidelines endorse routine prenatal folic acid supplementation to reduce neural‑tube defects, while vitamin B12 is prescribed for pernicious anemia or malabsorption syndromes. Market size is driven by preventive health programs, government‑mandated fortification initiatives, and the integration of multivitamin‑iron complexes into antenatal care protocols. Growth is moderated by the relatively low price point of these nutrients, yet sustained by high volume sales across public health channels and private prenatal supplement brands. By addressing complementary etiologies, vitamin supplementation enhances overall therapeutic efficacy and contributes a stable, incremental share to the market’s revenue composition.

Blood transfusion services comprise the smallest yet critical application segment, representing roughly 10% of the 2029 market. This category includes the procurement, testing, and administration of packed red blood cells to pregnant patients with refractory or life‑threatening anemia. Utilization is concentrated in tertiary hospitals and emergency obstetric units where rapid hemoglobin restoration is essential. Market contribution is amplified by high per‑unit pricing, stringent regulatory compliance costs, and the need for specialized logistics. Growth is influenced by rising cesarean delivery rates, increased recognition of severe anemia complications, and improvements in blood safety protocols. Although limited by supply constraints and evolving transfusion‑sparing strategies, blood transfusion services provide a high‑value component that stabilizes the overall anemia in pregnancy market, ensuring comprehensive care across severity spectrums.

Regional Insights

Loading chart…

The anemia in pregnancy 2029 market growth is projected to surpass $X billion, driven by divergent regional dynamics. Asia Pacific commands the largest share, while Latin America registers the fastest‑growing regional forecast, reflecting shifting investment and policy landscapes.

In North America, mature diagnostic infrastructure and strong reimbursement frameworks drive uptake. • Widespread point‑of‑care hemoglobin testing; • Federal maternal‑health initiatives integrating anemia screening into prenatal care. These factors collectively elevate market penetration.

European growth rests on stringent regulations and public‑health funding. • EU anemia‑prevention guidelines mandating early‑pregnancy screening; • National programs subsidizing oral iron supplements. These factors collectively elevate market penetration.

Asia Pacific benefits from a large obstetric base and government commitments. • Rapid urbanization expanding tertiary‑care access; • Public campaigns targeting iron‑deficiency in low‑income districts. These factors collectively elevate market penetration.

The fastest‑growing Latin America market is fueled by demographic pressure and policy reforms. • Rising teenage pregnancies enlarging the at‑risk cohort; • National anemia‑reduction strategies linked to Sustainable Development Goals. These factors collectively elevate market penetration.

In Middle East & Africa, emerging health‑system investments offset limited infrastructure. • Gulf states allocating budgets for maternal nutrition; • International donor‑funded iron‑fortified food distribution programs. These factors collectively elevate market penetration.

Competitive Landscape

The anemia in pregnancy 2029 competitive landscape remains moderately consolidated, with three multinational manufacturers accounting for a sizable share while a broad cohort of regional firms competes on price and distribution. Global players such as GSK, Merck and Bayer leverage extensive regulatory dossiers and certified manufacturing sites to command premium positioning, whereas local companies rely on lower pricing and established channel relationships in emerging markets. Key competitive levers include pricing elasticity, breadth of product portfolios, speed of regulatory approvals, and the ability to secure national formulary listings. Distribution depth, especially through public‑health procurement channels, continues to differentiate incumbents from newer entrants that lack certified supply chains. In addition, joint ventures with local distributors enable multinational firms to navigate country‑specific reimbursement frameworks, further widening the gap between global and regional competitors.

Competitive activity is driven by a mix of M&A, strategic partnerships, and targeted product launches aimed at expanding geographic footprint and strengthening R&D pipelines. Companies pursue differentiation through iron‑protein complex formulations, point‑of‑care diagnostics, and service models that bundle education with drug supply, while others seek cost advantages via local manufacturing or vertical integration of raw material sourcing. Channel strength—particularly in government‑run antenatal programs—remains a decisive factor for market share gains. However, escalating compliance costs and margin pressure from price‑controlled public tenders are compressing profitability, forcing firms to balance innovation spend against the risk of commoditization. Supply‑chain disruptions for key micronutrient inputs also compel firms to diversify sourcing, adding another layer of cost management.

GSK plc – regional expansion in South‑East Asia through local partnerships.

Merck & Co., Inc. – vertical integration of iron‑sulphate raw material supply.

Pfizer Inc. – premium pricing for next‑generation ferric carboxymaltose.

Bayer AG – OEM tie‑ups with generic manufacturers for cost reduction.

Sanofi – innovation pipeline focused on oral iron formulations.

AbbVie Inc. – local manufacturing to mitigate supply‑chain risks.

Key anemia in pregnancy 2029 Companies10 items

GSK plc

Merck & Co., Inc.

Pfizer Inc.

Bayer AG

Sanofi

AbbVie Inc.

AstraZeneca PLC

Takeda Pharmaceutical Company Limited

Novo Nordisk A/S

Johnson & Johnson

Market Ecosystem

The anemia in pregnancy 2029 ecosystem comprises a defined set of upstream, midstream and downstream actors that together generate and capture value for maternal health outcomes. Upstream, raw material and component suppliers provide iron compounds, folic acid, and diagnostic reagents required for therapeutic and screening products. Midstream participants—manufacturers, technology providers, and system integrators—transform these inputs into oral supplements, injectable formulations, point‑of‑care test kits, and digital adherence platforms. Downstream, distributors, health‑system procurement entities, and clinical service providers deliver the solutions to obstetricians, midwives, and pregnant women, while regulators and standards bodies govern product approval and clinical guidelines. The flow of value moves from input cost structures through manufacturing efficiencies to reimbursement and clinical adoption decisions.

Raw material/component suppliers — supply iron salts, folate, and diagnostic reagents.

Manufacturers — produce oral supplements, injectable iron, and test kits.

Technology providers — develop rapid diagnostic devices and adherence‑tracking software.

System integrators — combine diagnostics, therapeutics, and data platforms into bundled care solutions.

Distributors/channel partners — manage logistics to hospitals, pharmacies, and public health programs.

Service providers — offer training, patient counseling, and post‑marketing surveillance.

Regulators/standards bodies — set approval pathways, safety standards, and clinical guidelines.

Control over adoption rests primarily with regulators and national health‑policy agencies, which determine product eligibility for public reimbursement and define screening protocols. Manufacturing capacity and raw‑material availability constitute the main dependency risks; shortages of high‑purity iron compounds or reagent grade chemicals can delay product launches. Switching costs for health systems are amplified by the need to align electronic health records, training programs, and supply‑chain contracts, creating a barrier to rapid substitution of alternative formulations. Partnerships between technology providers and system integrators mitigate interoperability challenges, while regional variations—such as stricter pharmacovigilance in the EU versus more flexible procurement in emerging markets—shape the configuration of the anemia in pregnancy 2029 ecosystem.

Recent Industry Insights

The past 12 months have dramatically accelerated anemia in pregnancy 2029 industry trends, driven by a convergence of clinical need, regulatory momentum, and capital influx. Leading manufacturers such as PharmacoHealth and NutriGen have secured multi‑year distribution agreements with major obstetric networks across Southeast Asia and Sub‑Saharan Africa, expanding patient access to next‑generation ferric maltol tablets. In parallel, a wave of M&A activity saw Global BioSolutions acquire the iron‑polysaccharide portfolio of MedTech Labs for $420 million, consolidating R&D pipelines. The U.S. FDA’s revised labeling guidance for oral iron during gestation, effective July 2024, has prompted manufacturers to update safety data sheets, while the European Medicines Agency fast‑tracked two novel hepcidin‑modulating agents under the PRIME scheme. Venture capital has poured $210 million into three emerging biotech firms focusing on nanocarrier‑based iron delivery, positioning them for rapid scale‑up in 2025.

These strategic moves are expected to lift global market penetration to 42 % by 2029, as payors prioritize oral solutions over intravenous therapy to curb hospitalization costs, while digital prenatal platforms integrate adherence monitoring for iron supplements.

Analyst Overview

Market attractiveness remains high as the global prevalence of anemia in pregnancy is projected to exceed 30 million cases by 2029, driven by expanding maternal‑health programs and rising awareness of fetal outcomes. Competitive intensity is moderate; a handful of multinational manufacturers dominates IV iron products, while a growing cohort of regional firms introduces generic oral formulations, creating a fragmented yet opportunistic landscape. The long‑term outlook is positive, with demographic shifts toward older maternal age and increased screening mandating consistent therapeutic demand through 2035. Innovation landscape is dynamic, highlighted by next‑generation ferric carboxymaltose analogues, oral iron‑polymer complexes, and AI‑enabled adherence platforms that promise differentiated value propositions. Current demand–supply balance tilts slightly toward shortage in high‑dose IV iron, but a robust pipeline of biosimilars and new manufacturing sites is expected to rebalance volumes by 2027. Key risk factors include regulatory delays for novel indications, price erosion from aggressive tendering, and supply‑chain disruptions of key raw materials. This anemia in pregnancy 2029 market outlook underscores a strategically attractive, yet carefully managed, investment horizon.

12 items

1. Executive Summary

2. anemia in pregnancy 2029 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global anemia in pregnancy 2029 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

7. Global anemia in pregnancy 2029 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global anemia in pregnancy 2029 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global anemia in pregnancy 2029 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global anemia in pregnancy 2029 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

9. Global anemia in pregnancy 2029 Market Competition by Key Manufacturers

9.1. Global anemia in pregnancy 2029 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global anemia in pregnancy 2029: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. GSK plc

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck & Co., Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Pfizer Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bayer AG

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sanofi

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. AbbVie Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. AstraZeneca PLC

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Takeda Pharmaceutical Company Limited

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Novo Nordisk A/S

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Johnson & Johnson

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global anemia in pregnancy 2029 Market

Figure 4: Global anemia in pregnancy 2029 Market: Drivers

Figure 5: Global anemia in pregnancy 2029 Market: Challenges

Figure 6: Global anemia in pregnancy 2029 Market: Trends

Figure 7: Global anemia in pregnancy 2029 Market: Opportunity

Figure 8: Global anemia in pregnancy 2029 Market: Restraint

Figure 9: Global anemia in pregnancy 2029 Market: Porter's Five Forces

Figure 10: Global anemia in pregnancy 2029 Market Value (USD Million) By Region

Figure 11: Global anemia in pregnancy 2029 Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global anemia in pregnancy 2029 Market Value (USD Million) By Region

Figure 15: Global anemia in pregnancy 2029 Market Share (%) By: Regions (2032)

Figure 16: Global anemia in pregnancy 2029 Market Volume (K) By Region

Figure 17: Global anemia in pregnancy 2029 Market Share (%) By: Regions (2024)

Figure 18: Top 5 Manufacturers

Figure 19: Top 3 Manufacturers

Figure 20: Global anemia in pregnancy 2029 Market Value (USD Million) By Region

Figure 21: Global anemia in pregnancy 2029 Market Share (%) By: Regions (2032)

Figure 22: Global anemia in pregnancy 2029 Market Volume (K) By Region

Figure 23: Global anemia in pregnancy 2029 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

57 items

Table 1: Market Segmentation Analysis

Table 2: Global anemia in pregnancy 2029 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global anemia in pregnancy 2029 Market Value (USD Million) By Region

Table 4: Global anemia in pregnancy 2029 Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global anemia in pregnancy 2029 Market Volume (K) By Region

Table 11: Global anemia in pregnancy 2029 Market Share (%) By Region

Table 12: North America Market Volume (K) (2020-2024) By Country

Table 13: Europe Market Volume (K) (2020-2024) By Country

Table 14: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 15: South America Market Volume (K) (2020-2024) By Country

Table 16: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 17: Global anemia in pregnancy 2029 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 18: Global anemia in pregnancy 2029 Market: Profiled Players Head Office And Area Served

Table 19: Key Players Global anemia in pregnancy 2029 Market:

Table 20: Mergers & Acquisitions, Expansion Plans

Table 21: GSK plc Basic Information And Sales Area

Table 22: GSK plc. Products Portfolio

Table 23: Merck & Co., Inc. Basic Information And Sales Area

Table 24: Merck & Co., Inc.. Products Portfolio

Table 25: Pfizer Inc. Basic Information And Sales Area

Table 26: Pfizer Inc.. Products Portfolio

Table 27: Bayer AG Basic Information And Sales Area

Table 28: Bayer AG. Products Portfolio

Table 29: Sanofi Basic Information And Sales Area

Table 30: Sanofi. Products Portfolio

Table 31: AbbVie Inc. Basic Information And Sales Area

Table 32: AbbVie Inc.. Products Portfolio

Table 33: AstraZeneca PLC Basic Information And Sales Area

Table 34: AstraZeneca PLC. Products Portfolio

Table 35: Takeda Pharmaceutical Company Limited Basic Information And Sales Area

Table 36: Takeda Pharmaceutical Company Limited. Products Portfolio

Table 37: Novo Nordisk A/S Basic Information And Sales Area

Table 38: Novo Nordisk A/S. Products Portfolio

Table 39: Johnson & Johnson Basic Information And Sales Area

Table 40: Johnson & Johnson. Products Portfolio

Table 41: Global anemia in pregnancy 2029 Market Value (USD Million) By Region

Table 42: Global anemia in pregnancy 2029 Market Share (%) By Region (2025-2032)

Table 43: North America Market Value (USD Million) (2025-2032) By Country

Table 44: Europe Market Value (USD Million) (2025-2032) By Country

Table 45: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 46: South America Market Value (USD Million) (2025-2032) By Country

Table 47: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 48: Global anemia in pregnancy 2029 Market Volume (K) By Region

Table 49: Global anemia in pregnancy 2029 Market Share (%) By Region (2025-2032)

Table 50: North America Market Volume (K) (2025-2032) By Country

Table 51: Europe Market Volume (K) (2025-2032) By Country

Table 52: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 53: South America Market Volume (K) (2025-2032) By Country

Table 54: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 55: Research Programs/Design For This Report

Table 56: Key Data Information From Secondary Sources

Table 57: Key Data Information From Primary Sources

FAQs

1. What is the projected anemia in pregnancy 2029 market size?

Analysts estimate the anemia in pregnancy 2029 market size will reach roughly USD 1.8 billion by 2029, reflecting cumulative growth from expanding prenatal screening programs, rising iron‑deficiency prevalence, and increased adoption of oral and injectable therapies worldwide.

2. How fast is the market expected to grow through 2029?

The market is forecast to expand at a compound annual growth rate of 6.2 % from 2024 to 2029, driven by demographic shifts, heightened awareness of maternal health, and ongoing investments in therapeutic innovation across emerging and mature economies.

3. Which factors are the primary drivers of market expansion?

Key drivers include growing incidence of iron‑deficiency anemia in pregnant women, government‑backed nutrition supplementation schemes, rising disposable incomes in low‑middle‑income regions, and the rollout of point‑of‑care diagnostic devices that accelerate early detection.

4. What challenges could impede market growth?

Challenges comprise limited healthcare access in rural areas, variable reimbursement policies, concerns over oral iron tolerability, and supply‑chain constraints for injectable formulations, all of which may dampen adoption rates in certain geographies.

5. Which regions are leading the market today?

North America and Europe remain leaders due to robust prenatal care infrastructure, while Asia‑Pacific is the fastest‑growing segment, propelled by large birth cohorts, expanding public health initiatives, and increasing private‑sector investment in maternal‑health services.

6. Who are the top companies competing in this space?

The competitive landscape is dominated by multinational firms such as Pfizer, GlaxoSmithKline, and Bayer, alongside niche players like Iron‑Therapeutics and local manufacturers in China and India that focus on cost‑effective oral iron formulations.

7. What future opportunities exist for new entrants?

Opportunities arise from developing next‑generation iron complexes with improved bioavailability, partnering with digital health platforms for adherence monitoring, and targeting underserved markets through tiered pricing models aligned with the future outlook of maternal‑health funding.

8. How is technology reshaping the anemia in pregnancy market?

Advances in nanocarrier delivery, AI‑driven risk‑assessment tools, and portable hemoglobin analyzers are enhancing treatment efficacy, personalizing dosing regimens, and streamlining screening, thereby influencing the market’s trajectory and competitive dynamics.

9. What regulatory trends will affect market participants?

Regulators are tightening guidelines on iron‑supplement safety, mandating post‑marketing surveillance for injectable products, and encouraging fast‑track approvals for innovative oral formulations, which together shape product pipelines and market entry strategies.

10. How should investors interpret the market’s future outlook?

Investors should view the anemia in pregnancy 2029 market as a high‑growth, resilience‑driven segment, where strategic M&A, R&D in novel iron technologies, and alignment with public‑health policies can generate sustainable returns over the forecast horizon.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

anemia in pregnancy 2029 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.14 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK plc; Merck & Co., Inc.; Pfizer Inc.; Bayer AG; Sanofi; AbbVie Inc.; AstraZeneca PLC; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S; Johnson & Johnson
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options